Back

Impact of SGLT2 inhibitors on liver-related outcomes in patients with heart failure - a population-based study in HK

2 September 2024 (08:33 - 08:52)
Organised by: Logo
Congress Presentation Part of: Repurposing anti-diabetic pharmacotherapy: the new cure for all evils? Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Ms Hai-Yue Yang

Queen Mary Hospital, Hong Kong (Hong Kong)

3 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on repurposing of diabetic medications: the new cure for all evils?
Associate Professor A. Navar (Dallas, US)
Slides Video
Presentation thumbnail
Combined sodium-glucose-transporters inhibitors (SGLT2i) and glucagon-like-peptide receptor agonist (GLP1ra) compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry
Doctor D. Garcia Vega (Ourense, ES)
Abstract Slides Video
Presentation thumbnail
Risk of Incident colorectal carcinoma in patients with type 2 diabetes on SGLT-2 inhibitor users: a population-based cohort study
Doctor G. Jong (Taichung, TW)
Abstract Slides Video

Access the full session

Session thumbnail
Repurposing anti-diabetic pharmacotherapy: the new cure for all evils?
Video

The Event

Event poster

ESC Congress 2024

2 September 2024 08:33 CET
You may be interested in
thumbnail
Congress Session
Repurposing anti-diabetic pharmacotherapy: the new cure for all evils?
thumbnail
Congress Presentation
Impact of SGLT2 inhibitor on renal function and cardiovascular outcomes in heart failure: Korean heart failure III registry
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources